ACHIEVE LIFE SCIENCES, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ACHV in the last 30 days.
See all $ACHV insider activity →Stifel initiated Achieve Life Sciences (ACHV) with a Buy rating, citing the potential of its smoking cessation drug cytisinicline. The firm set a $ price target, implying 134% upside from the September 29 close, according to analyst James Condulis.
Achieve Life (ACHV) director Richard Alistair Stewart sold 20,626 shares at an average price of $8.493, retaining 208,249 shares directly and 1,241 indirectly. The sale occurred on August 19, 2026, with prices ranging from $8.4536 to $8.52 per share.
Stewart Richard Alistair sold 20,626 shares of ACHIEVE LIFE SCIENCES, INC. (ACHV) at $8.49 ($0.18M total) on 2026-08-19.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ACHV (ACHIEVE LIFE SCIENCES, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ACHV coverage spans financial news, corporate actions and insider activity.
Analyst upgrade and price target may drive buying interest.
The insider sale suggests modest downside pressure on ACHV.
Insider sale may signal reduced confidence, but the amount is modest relative to total holdings.
This is a large passive stake disclosure that can affect takeover optics and near-term trading flows, but it does not claim control intent.
Near-term risk is FDA resubmission timing and manufacturing qualification execution; upside is no clinical efficacy or safety deficiencies and a funded path to resubmission.
AlphAI scores every news story that mentions ACHV with an AI model for sentiment and relevance, and aggregates insider trades from ACHIEVE LIFE SCIENCES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Stifel initiated Achieve Life Sciences (ACHV) with a Buy rating, citing the potential of its smoking cessation drug cytisinicline. The firm set a $ price target, implying 134% upside from the September 29 close, according to analyst James Condulis.
1 min readAchieve Life (ACHV) director Richard Alistair Stewart sold 20,626 shares at an average price of $8.493, retaining 208,249 shares directly and 1,241 indirectly. The sale occurred on August 19, 2026, with prices ranging from $8.4536 to $8.52 per share.
1 min readStewart Richard Alistair sold 20,626 shares of ACHIEVE LIFE SCIENCES, INC. (ACHV) at $8.49 ($0.18M total) on 2026-08-19.
1 min readAchieve Life Sciences (ACHV) reported that Logos Global Management LP and related funds filed a Schedule 13G showing passive beneficial ownership of 10,538,440 shares, or 9.99% of the class, based on 102,902,490 shares outstanding as of Aug. 11, 2026. Holdings include 6,951,032 shares, options for 1,000,000 shares, and warrants for 2,751,032 shares.
2 min readACHIEVE LIFE SCIENCES, INC. (ACHV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following
6 min readAchieve Life Sciences (Nasdaq: ACHV) reported Q2 2026 results and updates on cytisinicline for nicotine dependence. The FDA issued a Complete Response Letter on June 20, 2026 citing cGMP and labeling issues, with no clinical efficacy or safety deficiencies. Achieve closed a private placement up to $354M and expects NDA resubmission in Q4 2026 and potential FDA approval in H1 2027. Cash was $187.3M at June 30, 2026.
6 min readAchieve announced it closed a $261.5M securitization of newly originated HELOCs, its first deal of 2026 and ninth overall. The pool covers 3,129 lines with about $261.5M unpaid principal and $276.5M total credit line as of June 30. S&P Global Ratings and Morningstar DBRS assigned ratings to six rated and three unrated note classes.
2 min readAchieve closed a $261.5 million AAA-rated HELOC securitization on July 30, 2026, called ACHM Trust 2026-HE1, backed by 3,129 newly originated HELOCs. The deal has six rated note classes and three unrated classes, with weighted average seasoning of three months and weighted average combined LTV of 65.67%, according to the company.
3 min readACHIEVE LIFE SCIENCES, INC. (ACHV) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K --12-31 false 0000949858 BC 0000949858 2026-07-02 2026-07-02 0000949858 dei:OtherAddressMember 2026-07-02 2026-07-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act
1 min readAchieve Life Sciences (NASDAQ:ACHV) rose 9.3% to $5.38 on Thursday after closing at $4.92; it traded as high as $5.50 on volume of 725,384 shares. Analysts cited mixed views: Canaccord set a $13 target (buy) and HC Wainwright set $12 (buy), while Weiss downgraded to sell (d-). The company reported ($0.19) EPS vs ($0.30) consensus on May 12.
4 min read
